Drum Hill Capital’s AbbVie ABBV Stock Holding History

Drum Hill Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$245K	Hold	1,127	–	–	0.23%	39
2025 Q4	$258K	Hold	1,127	–	–	0.27%	40
2025 Q3	$261K	Hold	1,127	–	–	0.28%	41
2025 Q2	$209K	Hold	1,127	–	–	0.23%	46
2025 Q1	$236K	Buy	+1,127	New	+$219K	0.27%	41

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Drum Hill Capital's ABBV Position: Q1 2026 in Review

Drum Hill Capital held its AbbVie (ABBV) position steady in Q1 2026 at 1,127 shares worth $245K. The position accounts for 0.23% of the portfolio, ranked #39.

Drum Hill Capital first reported a position in ABBV in Q1 2025 and has held it in 5 quarters since. The position peaked at $261K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Drum Hill Capital held 1,127 shares of AbbVie worth $245K as of Q1 2026.
Drum Hill Capital left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.23% of Drum Hill Capital's portfolio in Q1 2026, its #39 holding.
Drum Hill Capital first reported a position in AbbVie in Q1 2025 and has held it in 5 quarters since.
Drum Hill Capital's AbbVie position peaked at $261K in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Drum Hill Capital's 13F filing for Q1 2026, filed 21 Apr 2026.